SORANIB acts as a tyrosine kinase inhibitor, suppressing tumor growth and metastasis. It is effective in treating liver cancer (hepatocellular carcinoma) and kidney cancer (metastatic renal cancer). The drug helps to slow the disease progression, improving the patient's quality of life. It is recommended for patients for whom surgery or radiotherapy is not an option.
The drug is used for the treatment of:
Liver cancer (hepatocellular carcinoma)
Metastatic kidney cancer
Cancerous tumors that are not amenable to surgical treatment
SORANIB is taken orally, typically 1 tablet (200 mg) twice daily, either 1 hour before meals or 2 hours after meals. The dosage may be adjusted by the doctor based on the patient's response and condition.
Contraindications:
Hypersensitivity to the components of the drug
Pregnancy and breastfeeding
Severe liver diseases
Heart and vascular disorders
Side Effects:
Nausea and vomiting
Diarrhea and dyspepsia
Fatigue, headache
Loss of appetite, weight loss
Skin rashes
